Xenon Pharmaceuticals (XENE) Posts Earnings Results, Misses Estimates By $0.16 EPS

Xenon Pharmaceuticals (NASDAQ:XENE) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.16), Fidelity Earnings reports.

Shares of Xenon Pharmaceuticals stock traded down $0.43 during mid-day trading on Wednesday, reaching $9.54. 4,008 shares of the stock were exchanged, compared to its average volume of 145,876. The stock has a market capitalization of $205.71 million, a P/E ratio of -5.69 and a beta of 1.20. The company has a quick ratio of 20.83, a current ratio of 20.83 and a debt-to-equity ratio of 0.41. Xenon Pharmaceuticals has a fifty-two week low of $2.10 and a fifty-two week high of $15.92.

A number of equities analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday. BidaskClub cut shares of Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 6th. Jefferies Financial Group reiterated a “buy” rating and set a $16.00 target price on shares of Xenon Pharmaceuticals in a research report on Friday, August 10th. Finally, Stifel Nicolaus increased their target price on shares of Xenon Pharmaceuticals from $9.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $14.33.

TRADEMARK VIOLATION NOTICE: This news story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/11/07/xenon-pharmaceuticals-xene-posts-earnings-results-misses-estimates-by-0-16-eps.html.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies.

Further Reading: What is the NASDAQ Stock Market?

Earnings History for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply